AstraZeneca elects to return AZD9412 drug rights to Synairgen
The AZD9412 is a novel inhaled interferon beta therapy, which is being developed to support the immune system by correcting a deficiency that makes vulnerable to respiratory tract
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
Several additional new investors participated in the financing, including GV (formerly Google Ventures) and Alexandria Venture Investments. The company’s existing investors, including OrbiMed, Polaris Venture Partners, SV Health